17 October 2022 in Clinical and Translational Medicine
Backgrounds: Decreased cytotoxicity of natural killer (NK) cells has been shown in multiple myeloma (MM). However, the underlying molecular mechanisms remain unclear. Here, by using single‐cell RNA sequencing analysis and in vitro experiments, we aim to uncover and validate molecularly distinctive insights into identifying regulators for NK cell exhaustion and provide potential targets for novel immune therapies in MM.Methods: Single‐cell RNA sequencing was conducted in the bone marrow and peripheral blood samples from 10 newly diagnosed MM patients and three healthy volunteers. Based on the cluster‐defining differentially expressed genes, we named and estimated functional states of each cluster via bioinformatics analyses. Functional significance of key findings obtained from sequencing analysis was examined in a series of in vitro experiments, including luciferase reporter assay, lentiviral expression vector construction, NK cell transfection, RT‐qPCR, flow cytometry, and cytotoxicity assay.Results: We classified NK cells into seven distinct clusters and confirmed that a subset of ZNF683+ NK cells were enriched in MM patients with ‘exhausted’ transcriptomic profile, featuring as decreased expression of activating receptors and cytolytic molecules, as well as increased expression of inhibitory receptors. Next, we found a significant downregulation of SH2D1B gene that encodes EAT‐2, an adaptor protein of activating receptor SLAMF7, in ZNF683+ NK cells from MM patients versus healthy volunteers. We further proved that ZNF683 transfection in NK cells significantly downregulated SH2D1B expression via directly binding to the promoter of SH2D1B, leading to NK cell cytotoxic activity impairment and exhausted phenotypes acquisition. In contrast, ZNF683 knockout in NK cells from MM patients increased cytotoxic activity and reversed NK cell exhaustion.Conclusions: In summary, our findings uncover an important mechanism of ZNF683+ NK cell exhaustion and suggest that transcriptional suppressor ZNF683 as a potential useful therapeutic target in immunotherapy of MM.
1 January 2022 in BioMed Research International
Several genes on chromosome 1q21 region predict a high risk of multiple myeloma (MM); however, the underlying molecular pathology remains elusive. Overexpression, amplification, or activation of SET Domain Bifurcated 1 (SETDB1), which is located on 1q21, is closely associated with poor prognosis of many human solid malignancies. In our study, upregulation of SETDB1 might indicate an unfavorable prognosis of MM using bioinformatics analysis from GEO databases and MMRF‐CoMMpass. Here, increased SETDB1 expression was observed in the plasma cells from newly diagnosed multiple myeloma patients compared to those from the normal controls. Meanwhile, SETDB1 overexpression was the result of increased copy numbers of SETDB1 gene. In MM patients, the Kaplan‐Meier analysis was employed to demonstrate that increased SETDB1 expression was associated with shorter overall survival (OS) and event‐free survival (EFS). Besides, we conducted multifactorial cox regression analysis to state that SETDB1 expression was an independent biomarker for OS and EFS. MM patients with higher SETDB1 expression showed higher levels of beta‐2 microglobulin (β2M), lactate dehydrogenase (LDH), and bone marrow biopsy plasma cells (BMPC) and lower levels of haemoglobin (HGB). Functional enrichment analysis suggested that SETDB1 could promote cell cycle progression in myeloma. Finally, we observed that SETDB1 was distinctly correlated with tumor immunity in MM. SETDB1 expression in myeloma cells was positively correlated with CD56dim natural killer cells but negatively correlated with infiltrating levels of type17 T helper cells, effector memory CD8 T cells, activated dendritic cells, and natural killer T cells from whole bone marrow (WBM) biopsies. Taken together, these results indicated that SETDB1 could be used as a novel biomarker for predicting the prognosis of MM patients.
7 August 2018 in IOP Conference Series: Materials Science and Engineering
Objective: this review aims to analyze six recently published to compare the MedDiet with different control diets including American Diabetes Association diet, low-fat diet, low-carbohydrate diet on the treatment and management of type 2 diabetes (T2D) in overweight adults, to evaluate the limitations for improving randomized controlled trials design on this field. Methods: full text and published articles were searched via following databases: Medline on OvidSP, CINAHL, Web of Science Core Collection, and Google Scholar. The select interval of this review was controlled from November 2009 to January 2017. All headings, abstracts, contents and references were selected with following mutual terms: "Mediterranean", "MedDiet", "type 2 diabetes", "dietary pattern", "insulin resistance", "insulin sensitivity", "RCTs" and "intervention". And then 114 studies were selected, but some of the unrelated articles (n = 109) were filtered by setting excluding criteria via Endnote: non-English publications (n = 2); the intervention period was less than three months (n = 0); duplicate publications (n = 13); non-RCTs studies (n = 94). Finally, only six eligible studies were included. Results: encouraging the use of extra virgin olive oil to reduce the intake of monounsaturated fatty acids in Mediterranean diets and increase exercise has a positive effect on the prevention of type 2 diabetes. In addition, the use of a low-carbohydrate Mediterranean diet can also prevent T2D. Conclusions: overweight and obese patients are more encouraged to adopt the Mediterranean diet to control their T2D.